Mangalam Drugs and Organics reports strong financial performance in Q1 FY25
Mangalam Drugs and Organics, a microcap pharmaceutical company, has recently announced its financial results for the quarter ended June 2024. The company has shown a positive performance with a score of 8, which is an improvement from the previous quarter’s score of 19.
One of the major highlights of the financial results is the significant growth in Profit After Tax (PAT) for the half-yearly period. The company has reported a PAT of Rs 6.23 crore, which is a remarkable increase of 144.72% compared to the same period last year. This trend is a positive sign for the company and shows its strong financial performance.
Moreover, the company has also surpassed its PAT for the previous twelve months in just half a year, indicating a strong growth trajectory. This is a testament to the company’s efficient management and strategic planning.
However, the company has seen a decline in its net sales for the quarter, which is a cause for concern. The net sales for the quarter stood at Rs 76.53 crore, a decrease of -17.0% compared to the average net sales of the previous four quarters. This trend is also reflected in the lowest net sales in the last five quarters.
Despite this, MarketsMOJO has given a ‘Buy’ call for Mangalam Drugs, which shows the potential of the company in the pharma industry. With its positive financial performance and strong growth potential, Mangalam Drugs is definitely a company to watch out for in the microcap segment.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
